

























Phenazepam is a 1-4 benzodiazepine that was developed in 1975 in the former USSR and is used clinically 
as an anxiolytic [1], anticonvulsant, hypnotic and for the treatment of ethanol withdrawal [2]. Outside of the 
former soviet bloc there has been evidence of the abuse of phenazepam around the world since 1999 [3], 
with reports of overdoses, driving under the influence of drug (DUID) cases and also deaths [4-8]. As with 
other benzodiazepines the deaths have usually involved other drugs as well as phenazepam rather than 
phenazepam in isolation [9]. This has led to the control of phenazepam around the world. Due to the 
apparent persistence of phenazepam as a drug of abuse it is important to have knowledge of the 
pharmacokinetics, in relation to forensic toxicology, to determine the maximum length of time the drug 
could be detected after death. Also, the possibility of redistribution of the drug, which could affect the 
postmortem concentrations.  The active metabolite of phenazepam, 3-hydroxy phenazepam and the parent 
drug are both full γ-aminobutyric acid type A (GABAA) receptor agonists [1] and are detectable in a variety 
of body fluids including subclavian, femoral and cardiac blood, urine, vitreous humour and tissues 
(thalamus, liver and psoas muscle) [9]. Due to phenazepam being developed in the former USSR there is 
limited information about it in the English literature with some publications being difficult to obtain. The 
current knowledge of phenazepam has been extensively reviewed in two fairly recent publications [1,8]. 
The limited information about the pharmacokinetics of phenazepam cited in these publications was only 
determined using two subjects (oral doses of 3mg and 5mg [10]) and intravenous/intramuscular injection in 
six subjects with a single dose of 2mg [11]. These studies gave a limited insight into the pharmacokinetics 
but was missing important information (such as the volume of distribution) and gave unclear results about 
the half-life (t½) with a range of 15h (via injection) and 60h (oral) [10, 11] . The authors recently obtained 
the Russian book “Phenazepam: 25 Years in Medical Practice” [12] containing a thesis based upon the 
pharmacokinetics of phenazepam which has allowed us to obtain further information [13]. In the thesis they 
describe a study where six patients were administered a single oral dose between 3 - 5mg and serial blood 
samples were taken and measured over 301 hours [13]. This new data has allowed us to update the 
information about phenazepam pharmacokinetics, particularly the information on the volume of distribution 
(V), half-life (t1/2), oral plasma clearance (CL) and absorption half-life (t1/2), which we have summarised 
below in table 1. It is interesting to note that the t½ of phenazepam appears to be significantly greater than 
60 h reported in a previous study [10] with the new study giving a t½ (mean) of 140 h (range 48.8 – 301.0 
h) [13]. This may account for the long duration of side effects observed in previous overdose cases [14]. 
This revised information will allow for more accurate interpretation of the drug in both the clinical setting for 
back calculations, which would be useful in jurisdictions that have blood levels for DUID offences such as 






Parameter  Value Dose/route  Number of cases (n) [REF]
Volume of Distribution (V)  1.01 ‐ 2.15 L/kg 3 – 5 mg (oral)  6 [13]
Absorption Half‐Life (t1/2)  0.26 – 1.18 h  (median: 0.61 h) 3 – 5 mg (oral)  6 [13]
Elimination Half‐Life (t1/2) – 
Injection 
14.9 h (IV), 15.6h (IM)  2 mg (IV or IM)  6 [11]
Elimination Half‐Life (t1/2) ‐ Oral  49 ‐ 301h (median: 103 h) 3 – 5 mg ( oral)  6 [13]
Bioavailability (F)  0.82 2 mg (IV or IM)  6 [11]
Maximum plasma 
concentration (Cmax) 
0.024 µg/mL (3mg), 0.038 µg/mL (5mg) 3 or 5 mg (oral)  2 [10]
 Time to maximum plasma 
concentration (Tmax) 
~2 ‐ 4h  3 or 5 mg (oral)  2 [10], 6 [13]








0.044 min‐1 (IM), 0.047 min‐1 (IV)  2 mg (IV or IM)  6 [11]
Plasma clearance (CL) – 
Injection 
220.43 ml/hr (IV), 267.93 ml/hr (IM) 2 mg (IV or IM)  6 [11]
Plasma clearance (CL) – Oral  2.53 ‐ 27.90 ml/kg/h (Median: 10.1 ml/kg/h) 3‐5 mg (oral)  6 [13]
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